These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15804323)

  • 1. The economic burden of anemia in cancer patients receiving chemotherapy.
    Lyman GH; Berndt ER; Kallich JD; Erder MH; Crown WH; Long SR; Lee H; Song X; Finkelstein SN
    Value Health; 2005; 8(2):149-56. PubMed ID: 15804323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of patients with anemia in selected diseases.
    Ershler WB; Chen K; Reyes EB; Dubois R
    Value Health; 2005; 8(6):629-38. PubMed ID: 16283863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of anaemia and its treatment on employee disability and medical costs.
    Berndt E; Crown W; Kallich J; Long S; Song X; Lyman GH
    Pharmacoeconomics; 2005; 23(2):183-92. PubMed ID: 15748092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden of anemia in an insured population.
    Nissenson AR; Wade S; Goodnough T; Knight K; Dubois RW
    J Manag Care Pharm; 2005 Sep; 11(7):565-74. PubMed ID: 16137214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia therapy: individual benefit and societal cost.
    Denton TA; Diamond GA; Matloff JM; Gray RJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of treating seriously mentally ill persons with HIV following highly active retroviral therapy (HAART).
    Rothbard AB; Lee S; Blank MB
    J Ment Health Policy Econ; 2009 Dec; 12(4):187-94. PubMed ID: 20195006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies.
    Henry DH; Abels RI
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):21-8. PubMed ID: 8202722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.
    Moyneur E; Bookhart BK; Mody SH; Fournier AA; Mallett D; Duh MS
    Dis Manag; 2008 Feb; 11(1):49-58. PubMed ID: 18279115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O; Bailey RA; Stephenson JJ; Singer J
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of fruit and vegetable consumption in middle-aged men to medicare expenditures in older age: the Chicago Western Electric Study.
    Daviglus ML; Liu K; Pirzada A; Yan LL; Garside DB; Wang R; Van Horn L; Manning WG; Manheim LM; Dyer AR; Greenland P; Stamler J
    J Am Diet Assoc; 2005 Nov; 105(11):1735-44. PubMed ID: 16256757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy.
    Henry DH; Brooks BJ; Case DC; Fishkin E; Jacobson R; Keller AM; Kugler J; Moore J; Silver RT; Storniolo AM; Abels RI; Gordon DS; Nelson R; Larholt K; Bryant E; Rudnick S
    Cancer J Sci Am; 1995; 1(4):252-60. PubMed ID: 9166485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
    Bennett CL; Calhoun EA
    Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
    Quirt I; Micucci S; Moran LA; Pater J; Browman G
    Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.